Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 21;2(1):ltac021.
doi: 10.1093/immadv/ltac021. eCollection 2022.

TIM-3: a tumor-associated antigen beyond checkpoint inhibition?

Stefan Barth  1   2 , Krupa Naran  1
Affiliations

TIM-3: a tumor-associated antigen beyond checkpoint inhibition?

Stefan Barth et al. Immunother Adv. .

Erratum in

Abstract

Immune checkpoint inhibitors are one of the most remarkable immunomodulatory therapies of current times. Sabatolimab is a high-affinity, humanized anti-TIM-3 monoclonal antibody currently in development for patients with myeloproliferative disorders, including acute myeloid leukemia and myelodysplastic syndromes. By targeting TIM-3, a receptor expressed on various immune effector cells as well as myeloid cells, multiple mechanisms of action that are distinct from canonical immune checkpoint inhibitors are in play - (i) blockade of TIM-3 and its ligands PtdSer/galectin-9, (ii) modulation of leukemic cell self-renewal as well as (iii) antibody-dependent phagocytosis of TIM-3-expressing leukemic cells. Novel immunotherapies such as sabatolimab which enhance the antitumor immune response on converging fronts represent the promise of a continuously replenished armoury for the treatment of cancer.

Keywords: TIM-3; antigen; checkpoint; inhibition; tumor-associated.

PubMed Disclaimer

Conflict of interest statement

Stefan Barth is a Regional Editor of Immunotherapy Advances and as such has been blinded from reviewing or making decisions on the manuscript.

Similar articles

See all similar articles

References

    1. Jerne NK. The natural-selection theory of antibody formation. PNAS 1955; 41(11):849–57. 10.1073/pnas.41.11.849 - DOI - PMC - PubMed
    1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495–7. doi:10.1038/256495a0 - DOI - PubMed
    1. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer: new insights, new targets. Cell 2012; 148(6):1081–4. 10.1016/j.cell.2012.02.034 - DOI - PMC - PubMed
    1. Naran K, Nundalall T, Chetty S et al. . Principles of immunotherapy: implication for treatment strategies in cancer and infectious diseases. Front Microbiol 2018; 9:3158. 10.3389/fmicb.2018.03158 - DOI - PMC - PubMed
    1. Ramamurthy D, Nundalall T, Cingo S et al. . Recent advances in immunotherapies against infectious diseases. Immunother Adv 2020; 1(1):itaa007. 10.1093/immadv/Itaa007 - DOI - PMC - PubMed

LinkOut - more resources